Advertisement

Journal of Echocardiography

, Volume 17, Issue 4, pp 177–186 | Cite as

Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments

  • Katsuomi IwakuraEmail author
Review Article
  • 241 Downloads

Abstract

Heart failure is one of the major cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) and increases the risk of morbidity and mortality. Although active management for heart failure is needed in patients with T2DM, traditional treatment and some new class of antihyperglycemic drugs, such as glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, could not reduce the risk of heart failure. Recent major trials demonstrated sodium–glucose co-transporter-2 (SGLT2) inhibitors improve prognosis of T2DM patients through prevention of heart failure. Both heart failure with reduced ejection fraction and that with preserved ejection fraction (HFpEF) is observed in T2DM patients, and HFpEF is often overlooked and misdiagnosed in these population. Left ventricular hypertrophy, left atrial dilatation, diastolic dysfunction, and subclinical systolic dysfunction indicated as reduced global longitudinal strain are major abnormalities on echocardiography in patients with diabetic cardiomyopathy. These structural and functional changes are also prevalent in the general patients with T2DM, and those with these abnormalities have higher incidence of heart failure than those without them. Glycemic control might improve some of these abnormalities on echocardiography, but it is still unclear whether their improvement could be associated with risk reduction for heart failure. At now, there are only limited data on the effects of DPP-4 inhibitors or SGLT2 inhibitors on echocardiography in T2DM patients. Large-scale trials are needed to clarify how antihyperglycemic drugs affect echocardiographic parameters.

Keywords

Diabetes mellitus Heart failure Hypertrophy Diastolic function Global longitudinal strain 

Notes

Compliance with ethical standards

Conflict of interest

The author received honoraria from AstraZeneca, Ono pharmaceutical, Boehringer-Ingelheim, Eli Lilly and Company, Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi-Sankyo.

Supplementary material

12574_2019_446_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. 1.
    Elley CR, Kenealy T, Robinson E, et al. Glycated haemoglobin and cardiovascular outcomes in people with type 2 diabetes: a large prospective cohort study. Diabet Med. 2008;25:1295–301.PubMedGoogle Scholar
  2. 2.
    Castagno D, Baird-Gunning J, Jhund PS, et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J. 2011;162(938–948):e2.Google Scholar
  3. 3.
    Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–88.CrossRefGoogle Scholar
  4. 4.
    Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation. 2019;140:e294–324.CrossRefGoogle Scholar
  5. 5.
    Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:853–72.CrossRefGoogle Scholar
  6. 6.
    Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.CrossRefGoogle Scholar
  7. 7.
    Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.CrossRefGoogle Scholar
  8. 8.
    Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.CrossRefGoogle Scholar
  9. 9.
    Vaur L, Gueret P, Lievre M, et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care. 2003;26:855–60.CrossRefGoogle Scholar
  10. 10.
    Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the strong heart study. J Am Coll Cardiol. 2001;37:1943–9.CrossRefGoogle Scholar
  11. 11.
    Aguilar D, Deswal A, Ramasubbu K, et al. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol. 2010;105:373–7.CrossRefGoogle Scholar
  12. 12.
    Skali H, Shah A, Gupta DK, et al. Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the atherosclerosis risk in the community study. Circ Heart Fail. 2015;8:448–54.CrossRefGoogle Scholar
  13. 13.
    De Marco M, de Simone G, Roman MJ, et al. Cardiac geometry and function in diabetic or prediabetic adolescents and young adults: the strong heart study. Diabetes Care. 2011;34:2300–5.CrossRefGoogle Scholar
  14. 14.
    Levelt E, Mahmod M, Piechnik SK, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 2016;65:44–52.PubMedGoogle Scholar
  15. 15.
    Moir S, Hanekom L, Fang Z-Y, et al. Relationship between myocardial perfusion and dysfunction in diabetic cardiomyopathy: a study of quantitative contrast echocardiography and strain rate imaging. Heart. 2006;92:1414–9.CrossRefGoogle Scholar
  16. 16.
    Ng ACT, Delgado V, Bertini M, et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2009;104:1398–401.CrossRefGoogle Scholar
  17. 17.
    Wang Y, Yang H, Huynh Q, et al. Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus: optimal parameters for prediction of heart failure. JACC Cardiovasc Imaging. 2018;11:1390–400.CrossRefGoogle Scholar
  18. 18.
    Boonman-De Winter LJMM, Rutten FH, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154–62.CrossRefGoogle Scholar
  19. 19.
    Ernande L, Audureau E, Jellis CL, et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol. 2017;70:1704–16.CrossRefGoogle Scholar
  20. 20.
    Leung M, Wong VW, Hudson M, et al. Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus. Circ Cardiovasc Imaging. 2016;9:1–9.CrossRefGoogle Scholar
  21. 21.
    Nogueira KC, Furtado M, Fukui RT, et al. Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor—a pilot study. Diabetol Metab Syndr. 2014;6:1–7.CrossRefGoogle Scholar
  22. 22.
    Fujiwara T, Yoshida M, Nakamura T, et al. Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients. Heart Vessels. 2015;30:696–701.CrossRefGoogle Scholar
  23. 23.
    Oe H, Nakamura K, Kihara H, et al. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial. Cardiovasc Diabetol. 2015;14:2–5.CrossRefGoogle Scholar
  24. 24.
    Leung M, Leung DY, Wong VW. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: a pilot study. Diabetes Vasc Dis Res. 2016;13:236–43.CrossRefGoogle Scholar
  25. 25.
    Yamada H, Tanaka A, Kusunose K, et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16:1–12.CrossRefGoogle Scholar
  26. 26.
    McMurray JJV, Ponikowski P, Bolli GB, et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail. 2018;6:8–17.CrossRefGoogle Scholar
  27. 27.
    Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39:e212–3.CrossRefGoogle Scholar
  28. 28.
    Matsutani D, Sakamoto M, Kayama Y, et al. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17:1–12.CrossRefGoogle Scholar
  29. 29.
    Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17:1–8.CrossRefGoogle Scholar
  30. 30.
    Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019.  https://doi.org/10.1161/CIRCULATIONAHA.119.042375.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Echocardiography 2019

Authors and Affiliations

  1. 1.Division of CardiologySakurabashi Watanabe HospitalOsakaJapan

Personalised recommendations